Target Name: MIR451A
NCBI ID: G574411
Review Report on MIR451A Target / Biomarker Content of Review Report on MIR451A Target / Biomarker
MIR451A
Other Name(s): hsa-mir-451 | hsa-mir-451a | mir-451a | MIR451 | MIRN451 | microRNA 451a | MicroRNA 451a | hsa-miR-451a

MIR451A: A Potential Drug Target and Biomarker

MIR451A, a non-coding RNA molecule, has been identified as a potential drug target and biomarker in various diseases, including cancer. Its unique structure and expression pattern make it an attractive target for researchers to investigate. In this article, we will discuss the research on MIR451A, its potential drug target status, and its role as a biomarker in various diseases.

Structure and Expression

MIR451A is a small non-coding RNA molecule that contains 24 amino acid residues. It has a unique structure, with a conserved highly folded secondary structure, mainly composed of 浼?-helices and 灏?-sheets (1-2). The MIR451A molecule contains some characteristic domains, such as a secondary domain composed of conserved amino acid residues, a double helix domain and a highly conserved terminal domain.

The expression levels of MIR451A vary widely in different tissues and organisms. It is expressed in a variety of cancers, including lung, liver, breast, and ovarian cancers. At the same time, it is also expressed to a certain extent in normal tissues. This difference suggests that MIR451A may have different functions in cancer and normal tissues and therefore may serve as a potential drug target or biomarker.

Potential Drug Target

MIR451A has been identified as a potential drug target due to its unique structure and expression pattern. The conserved amino acid residues in the MIR451A molecule make it a potential target for small molecules. Additionally, its expression pattern in various diseases, including cancer, suggests that it plays an important role in the development and progression of these diseases.

Studies have shown that MIR451A can be targeted by small molecules, including inhibitors, peptides, and antibodies. In particular, a small molecule inhibitor, called ML-862, has been shown to inhibit MIR451A-mediated signaling pathways in cancer cells. This suggests that MIR451A may be a useful target for cancer treatment.

Biomarker

MIR451A has also been identified as a potential biomarker in various diseases. Its unique expression pattern and conservation of amino acid residues make it a potential protein biomarker. In cancer, MIR451A has been shown to be involved in the development and progression of various cancers. For example, a study by Kim et al. found that high expression of MIR451A was associated with poor prognosis in patients with pancreatic ductal adenocarcinoma, a type of pancreatic cancer.

Another study by Zhang et al. found that MIR451A was expressed in various tissues and was associated with the development of neuroendocrine tumors, including pituitary thyroid carcinoma and secodontofacial odontoma.

In conclusion, MIR451A is a unique non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases. Its conserved structure and expression pattern make it an attractive target for researchers to investigate. Further studies are needed to determine its role as a drug target and biomarker in various diseases.

Protein Name: MicroRNA 451a

The "MIR451A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR451A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR451B | MIR452 | MIR4520-1 | MIR4520-2 | MIR4521 | MIR4524A | MIR4524B | MIR4525 | MIR4526 | MIR4527 | MIR4527HG | MIR4529 | MIR4530 | MIR4531 | MIR4533 | MIR4534 | MIR4535 | MIR4536-1 | MIR4536-2 | MIR4537 | MIR4538 | MIR4539 | MIR454 | MIR4540 | MIR455 | MIR4632 | MIR4633 | MIR4634 | MIR4635 | MIR4638 | MIR4639 | MIR4640 | MIR4641 | MIR4642 | MIR4644 | MIR4645 | MIR4646 | MIR4647 | MIR4648 | MIR4649 | MIR4650-1 | MIR4650-2 | MIR4651 | MIR4652 | MIR4653 | MIR4655 | MIR4656 | MIR4657 | MIR4658 | MIR4659A | MIR4659B | MIR466 | MIR4660 | MIR4661 | MIR4662A | MIR4663 | MIR4664 | MIR4665 | MIR4666A | MIR4666B | MIR4667 | MIR4668 | MIR4669 | MIR4670 | MIR4671 | MIR4672 | MIR4673 | MIR4674 | MIR4675 | MIR4676 | MIR4677 | MIR4679-1 | MIR4679-2 | MIR4680 | MIR4681 | MIR4684 | MIR4685 | MIR4686 | MIR4687 | MIR4688 | MIR4689 | MIR4690 | MIR4691 | MIR4692 | MIR4693 | MIR4694 | MIR4695 | MIR4697 | MIR4697 host gene (non-protein coding) | MIR4698 | MIR4699 | MIR4700 | MIR4701 | MIR4703 | MIR4704 | MIR4706 | MIR4707 | MIR4708 | MIR4709 | MIR4711